Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2013
Home
2013
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Appendix 4E and Preliminary Final Report
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Change in substantial holding
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Date of Annual General Meeting
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Cellmid CEO Presents at Brokers Meet Biotech
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Independent Valuation Report of Advangen Inc Japan
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Cellmid Signs Major Japanese Distribution Agreement
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Midkine antibodies effective in cancer
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
R&D Tax refund received
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Key European Patent for Anti-Midkine Antibodies Granted
Prev page
1
2
3
4
5
6
Next page
